en · de · es · pt
cjc-1295-notes.peptides6155.com › Blog › Compound Identity And Development History — Questions and Answers

Compound Identity And Development History — Questions and Answers

By Editorial Desk · published 2026-01-08 · last reviewed 2026-02-01 · Blog

The short version of Reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-01. Anything still debated is marked as such rather than presented as settled.

Compound Identity and Development History

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Background and Receptor Mechanism

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Handling Storage And Analytical Methods

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Related pages on this site

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Notes from published material

Iranian officials described the attack as an attempt to derail diplomacy, noting that Kharazi was overseeing a possible meeting between Iranian officials and US vice president JD Vance. Airstrikes on the strategically important Hengam Island in the Strait of Hormuz caused seven injuries. Netanyahu asserted that the US–Israeli strikes have eliminated Iran's ability to produce nuclear weapons and ballistic missiles, thereby removing "two existential threats" to Israel. Late in the day on 1 April, Trump made a speech addressing the nation, in which he said that the strikes have "dramatically curtailed" Iranian missile and drone systems, and added that the attacks on Iran will escalate over the next two to three weeks to "bring them back to the Stone Ages, where they belong". On 2 April, two US strikes on the B1 bridge between Tehran and Karaj, which was described as the highest bridge in the Middle East, reportedly killed eight people and wounded 95 others, causing it to collapse. Experts assessed the attack as a possible war crime; it was celebrated by Trump. At the time of the attack, many Iranian families had been gathered in the parks below the bridge to celebrate Sizdah Be-dar. Iran revealed major damage to the century-old medical center Pasteur Institute of Iran. US defense secretary Hegseth boasted of "death and destruction from the sky all day long". The IDF also announced that one of its strikes in the Kermanshah area of Iran killed Iranian ballistics missile chief Makram Atimi and several battalion commanders from Atimi's central Iranian ballistic missile unit.

=== Kosovo === → : Kosovar in Serbia Kosovo is still only a partially recognised state and the government of Serbia still claims the territory as its own. Due to Serbian refusal of Kosovo institutions, Serbs in North Kosovo act independently in sport. For example, the Football First League of North Kosovo was primarily formed of Serbian clubs from four of North Kosovo's municipalities. Both governments agreed upon creating a Community of Serb Municipalities. In 2016, Kosovo became the 55th member of UEFA, and therefore Football Federation of Kosovo's Football Superleague of Kosovo became a recognised independent league. From 2010 to 2015, the Football First League of North Kosovo was the top football regional league in North Kosovo, ranked fifth in the Serbian league system. The league was formed primarily of Serbian football clubs that come from four of North Kosovo's municipalities such as Leposavić, Zvečan, Zubin Potok and Northern Kosovska Mitrovica. The league was formed in protest to the establishment of the Kosovo Super League by the Republic of Kosovo; the Serbian clubs from North Kosovo refuse to enter the Republic of Kosovo's institutions as per the Assembly of the Community of Municipalities of the Autonomous Province of Kosovo and Metohija.

=== Protein evolution and origins of life === In addition to structural bioinformatics, Ben-Tal has worked on protein evolution and the emergence of protein architectures and functions. His laboratory describes this research as addressing how novel protein structures and functions arise during molecular evolution. To trace the evolutionary history of proteins, Ben-Tal, Rachel Kolodny of University of Haifa and coworkers searched among large representative sets of proteins for segments that are similar in sequence (and often also in structure). They presented the results as a similarity network, using a methodology that they tailor-made for this study, showing that many proteins share smaller segments with each other. For example, they observed the same amino acid both within a short theme shared by many proteins and within a longer theme shared only by few. Next, they searched for themes that appear in different sequence and structural contexts within proteins, calling these bridging themes. They found many bridging themes, with an average length of about 40 residues. Interestingly, only about half of these also share a similar structure; the different environment may have induced a conformational change. Some of the bridging themes bind ligands, which attests to their functional importance. Another testimony to the evolutionary importance of these themes is the fact that some of the most ancient protein folds (e.g. Rossmann, P-loop, and TIM-barrel) were found to share them. The bridging themes may offer hints to the emergence of earliest protein families.

Sources: en.wikipedia.org

Background from the literature

=== Splitting of water === The bound metal ion, plus a glutamate-histidine pair, activates and splits a water molecule from the surrounding solution. This generates a hydroxide ion within the active site.

== Etymology == The word "cement" can be traced back to the Ancient Roman term opus caementicium, used to describe masonry resembling modern concrete that was made from crushed rock with burnt lime as binder. The volcanic ash and pulverized brick supplements that were added to the burnt lime, to obtain a hydraulic binder, were later referred to as cementum, cimentum, cäment, and cement. In modern times, organic polymers are sometimes used as cements in concrete.

Leukocyte activation syndrome QT interval prolongation (only one case of torsades de pointes was noted during clinical trials) Atrial fibrillation or flutter Other side effects include allergic skin reactions (including reactions at the injection site, injection site pain), gastrointestinal disturbances (diarrhea), various types of pain, visual disturbances, and bleeding. If the drug extravasates, local irritation and phlebitis may occur.

===== Drug antagonists ===== An antagonist is a drug that binds to a receptor without activating it, meaning it has no intrinsic activity. By occupying the receptor, it blocks or reduces the effect of an agonist, such as a drug, hormone, or neurotransmitter, that would normally bind to and activate the receptor. Antagonists are often described as receptor "blockers" and may be classified as competitive or irreversible. A competitive antagonist competes with an agonist for binding to the receptor. As the concentration of the antagonist increases, agonist binding is progressively inhibited, resulting in a decrease in the physiological response. A high concentration of an antagonist can completely inhibit the response. This inhibition can be reversed by increasing the agonist concentration, since the agonist and antagonist compete for binding to the receptor. Competitive antagonists, therefore, can be characterized as shifting the dose–response relationship for the agonist to the right. In the presence of a competitive antagonist, it takes an increased concentration of the agonist to produce the same response observed in the absence of the antagonist. An irreversible antagonist binds so strongly to the receptor that it renders the receptor unavailable for binding to the agonist. Irreversible antagonists may even form covalent chemical bonds with the receptor.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

Network